Fertility company Spermosens’ board has decided to draw down the entire available amount of SEK 4.85 million from the capital facility announced on May 7. This is stated in a press release from the company.The capital will be provided through directed issues of units, where each unit consists of one share and one free warrant. The subscription price for the shares shall correspond to a 15 percent discount to the volume-weighted average price over the next ten trading days.The warrants entitle the holder to subscribe for one new share at SEK 0.025 per share during a three-year period. Since board chairman Ulrik Spork and CEO Tore Duvold are participating, their issue must be handled at an extraordinary general meeting.